Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy

Table 4 Clinical trials of preemptive antiviral therapy for hepatitis B virus reactivation in patients with hepatitis B virus-related hepatocellular carcinoma

Ref.	Study type	Cancer therapy	No of patients (Tx vs control)	Antiviral therapy	HBV reactivation (Tx vs control)	P value
Nagamatsu et al[10]	Retrospective	TAI	17 (8 vs 9)	LAM	0% vs 67%	0.009
Jang et al[17]	RCT	TACL	73 (36 vs 37)	LAM	2.8% vs 29.7%	0.002
Kim et al[6]	Retrospective	TACE + RT	48 (16 vs 32)	LAM	0% vs 21.8%	0.048
Huang et al[35]	Prospective	Hepatectomy	164 (126 vs 38)	LAM, ETV, ADV, TBVD	1.6% vs 21.1%	< 0.001
Dan et al[38]	Retrospective	Hepatectomy, RFA	218 (68 vs 150)	LAM, ETV, LAM + ADV	2.9% vs 20.7%1	0.027
					0% vs 7.6%2	NS
Huang et al[37]	RCT	Hepatectomy	84 (40 vs 44)	TBVD	2.5% vs 31.8%	0.001
Huang et al[16]	Retrospective	Hepatectomy	1609 (150 vs 1459)	LAM, ETV, ADV	4.7% vs 20.1%	< 0.001

¹Data following hepatectomy;

²Data following RFA. HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; Tx: Treatment; RCT: Randomized controlled trial; TAI: Transarterial infusion chemotherapy; TACL: Transarterial chemo-lipiodolization; TACE: Transarterial chemo-embolization; RT: Radiotherapy; LAM: Lamivudine; ETV: Entecavir; ADV: Adefovir; TBVD: Telbivudine; NS: Not significant.